Multiple Myeloma

Adding Daratumumab to Multiple Myeloma Backbone Regimens May Improve PFS
October 16, 2020

Researchers indicated that these “findings are of direct clinical relevance and may help clinicians choose an optimal anti-myeloma regimen for patients with high-risk cytogenetic factors.”

FDA Grants Priority Review to Idecabtagene Vicleucel for Multiple Myeloma
September 22, 2020

The biologics license application for idecabtagene vicleucel is for the treatment of adult patients with multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.

Phase 3 TOURMALINE-MM2 Fails to Meet Primary End Point of PFS
September 10, 2020

The study is evaluating the addition of ixazomib (Ninlaro) to lenalidomide and dexamethasone versus lenalidomide and dexamethasone plus placebo in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.